JAMA:一秒率正常的肺功能下降(PRISm)人群临床结果研究

2021-12-15 MedSci原创 MedSci原创

与肺功能正常人群相比,一秒率正常的肺功能下降人群的死亡率、不良心血管和呼吸事件风险增加

慢性肺病是美国人口死亡的主要原因之一,最常见的慢性肺病是慢性阻塞性肺病(COPD),患者存在肺部气流阻塞,一秒用力呼气量/用力肺活量 (FEV1/FVC)小于0.70。非阻塞性肺功能异常,以FEV1和FVC对称性减少为特征,是一种限制性、未分类、非特异性的低肺功能,也称一秒率正常的肺功能下降(PRISm)。近日研究人员就美国成年PRISm发病率、相关性及其临床结果进行了考察。

NHLBI是一项回顾性研究,包括1971-2011年进行的9个美国普通人群队列汇总数据,包含65251 名参与者,年龄在18-102岁之间,其中53701 名参与者有基线肺功能数据,PRISm定义FEV1/FVC大于或等于0.70,FEV1占预计值百分比小于80%;阻塞性肺病的FEV1/FVC比值小于0.70;正常肺功能为FEV1/FVC比值大于或等于0.7,FEV1占预计值百分比大于等于80%。研究的主要终点为全因死亡率、呼吸相关疾病死亡率、冠心病(CHD)相关死亡率、呼吸相关事件(住院和死亡率)和CHD相关事件(住院和死亡率)。

参与者平均年龄53.2岁,56.4%为女性,48.5%的参与者从不吸烟者,4582人(8.5%)患有PRISm。相对于肺功能正常人群,PRISm的风险因素包括肥胖(患病率分别为48.3%和31.4%;患病率[PR]为1.68)、体重不足(患病率1.4% vs1.0%;PR:2.20)、女性(患病率分别为60.3% vs 59.0%;PR:1.07)和正在吸烟(患病率分别为25.2% vs17.5%;PR:1.33)。与肺功能正常人群相比,PRISm人群的全因死亡率(29.6/1000人年vs 18.0/1000人年;差异11.6/1000人年;调整后的危险比[HR]=1.50)、呼吸相关死亡率(2.1/1000人年vs 1.0/1000人年;差异,1.1/1000人年;调整后HR=1.95),CHD相关死亡率(5.4/1000人年vs 2.6/1000人年;差异,2.7/1000人年;调整后HR=1.55),呼吸相关事件风险(12.2/1000人年vs 6.0/1000人年;差异,6.2/1000人年;调整后HR=1.90)和CHD相关事件风险(11.7/1000人年vs 7.0/1000人年;差异,4.7/1000人年;调整后的HR=1.30)增加。

PRISm人群的不良临床结局风险

研究发现,与肺功能正常人群相比,一秒率正常的肺功能下降人群的死亡率、不良心血管和呼吸事件风险增加。

原始出处:

Emily S. Wan et al. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults. JAMA. December 14,2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898882, encodeId=290b1898882c7, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Jan 21 20:34:55 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941692, encodeId=720a194169270, content=<a href='/topic/show?id=57eb8203240' target=_blank style='color:#2F92EE;'>#肺功能下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82032, encryptionId=57eb8203240, topicName=肺功能下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 08 13:34:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080621, encodeId=6e8b1080621f9, content=学习了,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200913/14a20f57ad124155b59e7abcef010870/598e2998bb6746a29dc7cc27d6257a84.jpg, createdBy=d23f4759873, createdName=Blueangel, createdTime=Thu Dec 16 09:46:59 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080520, encodeId=ccaf108052097, content=于广泛期SCLC患者,铂类为基础的化疗是, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Dec 16 08:13:35 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080473, encodeId=4a7c10804e362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8c4880245, createdName=144b1194m13暂无昵称, createdTime=Wed Dec 15 23:34:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080433, encodeId=9b0a10804334a, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Dec 15 21:22:11 CST 2021, time=2021-12-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1898882, encodeId=290b1898882c7, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Jan 21 20:34:55 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941692, encodeId=720a194169270, content=<a href='/topic/show?id=57eb8203240' target=_blank style='color:#2F92EE;'>#肺功能下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82032, encryptionId=57eb8203240, topicName=肺功能下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 08 13:34:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080621, encodeId=6e8b1080621f9, content=学习了,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200913/14a20f57ad124155b59e7abcef010870/598e2998bb6746a29dc7cc27d6257a84.jpg, createdBy=d23f4759873, createdName=Blueangel, createdTime=Thu Dec 16 09:46:59 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080520, encodeId=ccaf108052097, content=于广泛期SCLC患者,铂类为基础的化疗是, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Dec 16 08:13:35 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080473, encodeId=4a7c10804e362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8c4880245, createdName=144b1194m13暂无昵称, createdTime=Wed Dec 15 23:34:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080433, encodeId=9b0a10804334a, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Dec 15 21:22:11 CST 2021, time=2021-12-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1898882, encodeId=290b1898882c7, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Jan 21 20:34:55 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941692, encodeId=720a194169270, content=<a href='/topic/show?id=57eb8203240' target=_blank style='color:#2F92EE;'>#肺功能下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82032, encryptionId=57eb8203240, topicName=肺功能下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 08 13:34:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080621, encodeId=6e8b1080621f9, content=学习了,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200913/14a20f57ad124155b59e7abcef010870/598e2998bb6746a29dc7cc27d6257a84.jpg, createdBy=d23f4759873, createdName=Blueangel, createdTime=Thu Dec 16 09:46:59 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080520, encodeId=ccaf108052097, content=于广泛期SCLC患者,铂类为基础的化疗是, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Dec 16 08:13:35 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080473, encodeId=4a7c10804e362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8c4880245, createdName=144b1194m13暂无昵称, createdTime=Wed Dec 15 23:34:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080433, encodeId=9b0a10804334a, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Dec 15 21:22:11 CST 2021, time=2021-12-15, status=1, ipAttribution=)]
    2021-12-16 Blueangel

    学习了,好文

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1898882, encodeId=290b1898882c7, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Jan 21 20:34:55 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941692, encodeId=720a194169270, content=<a href='/topic/show?id=57eb8203240' target=_blank style='color:#2F92EE;'>#肺功能下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82032, encryptionId=57eb8203240, topicName=肺功能下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 08 13:34:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080621, encodeId=6e8b1080621f9, content=学习了,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200913/14a20f57ad124155b59e7abcef010870/598e2998bb6746a29dc7cc27d6257a84.jpg, createdBy=d23f4759873, createdName=Blueangel, createdTime=Thu Dec 16 09:46:59 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080520, encodeId=ccaf108052097, content=于广泛期SCLC患者,铂类为基础的化疗是, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Dec 16 08:13:35 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080473, encodeId=4a7c10804e362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8c4880245, createdName=144b1194m13暂无昵称, createdTime=Wed Dec 15 23:34:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080433, encodeId=9b0a10804334a, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Dec 15 21:22:11 CST 2021, time=2021-12-15, status=1, ipAttribution=)]
    2021-12-16 查查佳佳

    于广泛期SCLC患者,铂类为基础的化疗是

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1898882, encodeId=290b1898882c7, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Jan 21 20:34:55 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941692, encodeId=720a194169270, content=<a href='/topic/show?id=57eb8203240' target=_blank style='color:#2F92EE;'>#肺功能下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82032, encryptionId=57eb8203240, topicName=肺功能下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 08 13:34:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080621, encodeId=6e8b1080621f9, content=学习了,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200913/14a20f57ad124155b59e7abcef010870/598e2998bb6746a29dc7cc27d6257a84.jpg, createdBy=d23f4759873, createdName=Blueangel, createdTime=Thu Dec 16 09:46:59 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080520, encodeId=ccaf108052097, content=于广泛期SCLC患者,铂类为基础的化疗是, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Dec 16 08:13:35 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080473, encodeId=4a7c10804e362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8c4880245, createdName=144b1194m13暂无昵称, createdTime=Wed Dec 15 23:34:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080433, encodeId=9b0a10804334a, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Dec 15 21:22:11 CST 2021, time=2021-12-15, status=1, ipAttribution=)]
    2021-12-15 144b1194m13暂无昵称

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1898882, encodeId=290b1898882c7, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Jan 21 20:34:55 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941692, encodeId=720a194169270, content=<a href='/topic/show?id=57eb8203240' target=_blank style='color:#2F92EE;'>#肺功能下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82032, encryptionId=57eb8203240, topicName=肺功能下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 08 13:34:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080621, encodeId=6e8b1080621f9, content=学习了,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200913/14a20f57ad124155b59e7abcef010870/598e2998bb6746a29dc7cc27d6257a84.jpg, createdBy=d23f4759873, createdName=Blueangel, createdTime=Thu Dec 16 09:46:59 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080520, encodeId=ccaf108052097, content=于广泛期SCLC患者,铂类为基础的化疗是, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Dec 16 08:13:35 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080473, encodeId=4a7c10804e362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8c4880245, createdName=144b1194m13暂无昵称, createdTime=Wed Dec 15 23:34:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080433, encodeId=9b0a10804334a, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Dec 15 21:22:11 CST 2021, time=2021-12-15, status=1, ipAttribution=)]
    2021-12-15 ms5000000518166734

    学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习

    0